Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
Edit Your Profile
GYNECOLOGIC ONCOLOGY
Journal
Overview
Research
Identifiers
Other
View All
Overview
publication venue for
Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation
. 152:145-150.
2019
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation
. 150:85-91.
2018
Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
. 147:257-261.
2017
Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
. 145:346-351.
2017
The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma
. 143:258-263.
2016
Early-stage clear cell ovarian carcinoma and the effect of adjuvant radiation on survival
. 141:79.
2016
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer
. 140:36-41.
2016
Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors
. 140:138-144.
2016
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
. 140:42-47.
2016
A model for estimating ovarian cancer risk: Application for preventive oophorectomy
. 139:242-247.
2015
The sooner the better: Genetic testing following ovarian cancer diagnosis
. 137:423-429.
2015
The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
. 134:462-467.
2014
Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients
. 131:667-673.
2013
Keeping it simple: Genetics referrals for all invasive serous ovarian cancers
. 130:329-333.
2013
Nonascites-forming advanced-stage serous ovarian cancer is related to a superior epithelial antigen presentation and enhanced infiltrating T-cell response
. 130:e132.
2013
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations
. 130:e42.
2013
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study
. 130:127-131.
2013
Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles
. 128:488-492.
2013
Height, weight, BMI and ovarian cancer survival
. 127:83-87.
2012
Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership
. 127:75-82.
2012
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
. 121:353-357.
2011
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation
. 121:163-168.
2011
Multimodal therapy in the treatment of vaginal adenocarcinoma arising from endocervicosis
. 120:158-159.
2011
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
. 119:451-456.
2010
Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy
. 119:22-25.
2010
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube
. 118:299-302.
2010
Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers
. 118:295-298.
2010
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation
. 118:155-159.
2010
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary
. 117:9-17.
2010
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study
. 116:442-446.
2010
Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: Is it time to change the gold standard?
. 116:28-32.
2010
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
. 115:135-137.
2009
A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer
. 113:195-199.
2009
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma
. 112:450-454.
2009
Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study
. 112:68-72.
2009
Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: A matched case-control study
. 110:168-171.
2008
Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1
. 109:384-387.
2008
Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening - A case report
. 107:136-139.
2007
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
. 106:453-460.
2007
Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care
. 105:747-756.
2007
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study
. 104:7-10.
2007
Uterine sarcoma occurring in a premenopausal patient after uterine artery embolization: A case report and review of the literature
. 104:260-263.
2007
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study
. 100:324-329.
2006
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
. 100:58-64.
2006
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
. 100:83-88.
2006
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium
. 100:160-165.
2006
Sigmoid impaction secondary to urinary stones: Case report and review of literature
. 97:234-237.
2005
The use of transrectal ultrasound to biopsy pelvic masses in women
. 95:552-556.
2004
Conversion of an incontinent urinary conduit to a continent urinary reservoir (Miami Pouch)
. 94:814-817.
2004
A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer
. 93:588-593.
2004
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study
. 93:144-148.
2004
Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies
. 89:420-423.
2003
Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy
. 85:397-403.
2002
Expression of glucose transporter-1 in cervical cancer and its precursors
. 86:138-143.
2002
How important is removal of the parametrium at surgery for carcinoma of the cervix?
. 84:145-149.
2002
Psychological adjustment to familial-genetic risk assessment for ovarian cancer: Predictors of nonadherence to surveillance recommendations
. 84:72-80.
2002
Radical vaginal trachelectomy after supracervical hysterectomy
. 85:545-547.
2002
Vaginal reconstruction at the time of pelvic exenteration: A surgical and psychosexual analysis of techniques
. 87:39-45.
2002
Allelotype of papillary serous peritoneal carcinomas
. 82:69-76.
2001
Changes in the demographics and perioperative care of stage IA(2)/IB1 cervical cancer over the past 16 years
. 81:133-137.
2001
A genetic epidemiological study of carcinoma of the fallopian tube
. 80:341-345.
2001
Pattern of lymph node metastases in clinically unilateral stage invasive epithelial ovarian carcinomas
. 80:56-61.
2001
Information needs and decisional preferences among women with ovarian cancer
. 77:357-361.
2000
A longitudinal study of psychological adjustment to familial genetic risk assessment for ovarian cancer
. 74:331-337.
1999
Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas
. 74:202-207.
1999
A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer
. 72:292-297.
1999
Primary uterine angiosarcoma
. 75:272-276.
1999
Psychological impact of screening for familial ovarian cancer: Reactions to initial assessment
. 65:197-205.
1997
Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer
. 64:425-430.
1997
LETTERS TO THE EDITOR
. 62:427-428.
1996
Patients' preferences for therapy in advanced epithelial ovarian cancer: Development, testing, and application of a bedside decision instrument
. 62:329-335.
1996
Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix
. 61:416-422.
1996
In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration
. 61:175-179.
1996
DOES AGGRESSIVE THERAPY IMPROVE SURVIVAL IN SUBOPTIMAL STAGE-IIIC-IV OVARIAN-CANCER - A CANADIAN-AMERICAN COMPARATIVE-STUDY
. 59:194-199.
1995
METAANALYSIS COMPARING CISPLATIN TOTAL-DOSE INTENSITY AND SURVIVAL
. 59:93-101.
1995
A PROSPECTIVE RANDOMIZED COMPARISON OF AN ATTACHED SILVER-IMPREGNATED CUFF TO PREVENT CENTRAL VENOUS CATHETER-ASSOCIATED INFECTION
. 58:92-100.
1995
A PHASE-I TRIAL OF CYCLOSPHOSPHAMIDE AND CARBOPLATINUM COMBINED WITH INTERLEUKIN-3 IN WOMEN WITH ADVANCED-STAGE OVARIAN-CANCER
. 56:387-394.
1995
LIPID-SOLUBLE ANTIOXIDANTS - BETA-CAROTENE AND ALPHA-TOCOPHEROL LEVELS IN BREAST AND GYNECOLOGIC CANCERS
. 55:72-77.
1994
HIGH-DOSE METHOTREXATE FOR GESTATIONAL TROPHOBLASTIC DISEASE
. 54:282-287.
1994
DIFFERENCES IN THE MORBIDITY OF RADICAL HYSTERECTOMY BETWEEN GYNECOLOGICAL ONCOLOGISTS
. 51:39-45.
1993
PLATINUM CHEMOTHERAPY DURING PREGNANCY FOR SEROUS CYSTADENOCARCINOMA OF THE OVARY
. 49:92-94.
1993
ENDOMETRIAL ADENOCARCINOMA - GENETIC-ANALYSIS SUGGESTING HERITABLE SITE-SPECIFIC UTERINE-CANCER
. 47:167-171.
1992
LYMPH-NODE SAMPLING IN PATIENTS WITH EPITHELIAL OVARIAN-CARCINOMA
. 47:143-145.
1992
Endometrial adenocarcinoma: Genetic analysis indicating heritable site-specific uterine cancer
. 45:81.
1992
Lymph node sampling in patients with epithelial ovarian carcinoma
. 45:77.
1992
Pilot clinical trial of cisplatin (CDDP), radiation therapy (RT), and WR2721 in carcinoma of the uterine cervix (CC)
. 45:85.
1992
Surgical management of patients with endometrial cancer and cervical involvement
. 45:97-98.
1992
CA-125 - A POTENTIAL PROGNOSTIC INDICATOR IN PATIENTS WITH CERVICAL-CANCER
. 40:222-224.
1991
CA125-a potential prognostic indicator in patients with cervical carcinoma?
. 40:189.
1991
The response of the small cell cancer of the ovary with hypercalcemia to sequencing chemotherapy
. 40:178.
1991
The role of anemia in predicting treatment outcome in locally advanced cervical carcinoma
. 40:186.
1991
A SUCCESSFUL TERM PREGNANCY FOLLOWING THE SYSTEMIC AND INTRAPERITONEAL ADMINISTRATION OF CISPLATIN CHEMOTHERAPY
. 39:378-380.
1990
HETEROGENEITY IN HORMONE RECEPTOR STATUS IN PRIMARY AND METASTATIC ENDOMETRIAL CANCER
. 38:437-441.
1990
OVARIAN CONSERVATION IN PLACENTAL SITE TROPHOBLASTIC TUMOR
. 37:239-243.
1990
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells
. 36:291.
1990
CONCOMITANT CISPLATIN AND RADIOTHERAPY IN LOCALLY ADVANCED CERVICAL-CARCINOMA
. 34:395-401.
1989
CONCURRENT RADIATION AND CHEMOTHERAPY IN VULVAR CARCINOMA
. 34:263-267.
1989
ARTERIAL EMBOLIZATION IN THE MANAGEMENT OF ABDOMINAL AND RETROPERITONEAL HEMORRHAGE
. 34:131-135.
1989
COLPOSCOPIC AND CYTOLOGIC DETECTION OF CHRONIC LYMPHOCYTIC-LEUKEMIA
. 34:106-108.
1989
IMMUNE-COMPLEXES IN OVARIAN-CARCINOMA
. 32:350-353.
1989
Clinical options: Small cell CA ovary
. 32:127.
1989
Concomitant cisplatin (DDP) and radiotherapy (RT) in locally advanced cervical carcinoma (CX CA)
. 32:126-127.
1989
Concurrent radiation and chemotherapy in vulvar carcinoma
. 32:122-123.
1989
Incidence of clostridium difficile (CD) infection in patients (pis.) with diarrhea (D) on a gynecologic oncology service
. 32:120.
1989
Ovarian cancer grows intraperitoneally due to growth factors present in ascitic fluid: Development of animal model systems and methods to block ascitic fluid growth factor activity
. 32:104.
1989
The Kock pouch in previously irradiated gynecological patients
. 32:127-128.
1989
CONTINUOUS INFUSION FLUOROPYRIMIDINES AS SALVAGE THERAPY FOR PATIENTS WITH ADVANCED OVARIAN-CARCINOMA
. 29:348-355.
1988
CATHETER COMPLICATIONS ASSOCIATED WITH INTRAPERITONEAL CHEMOTHERAPY
. 24:41-50.
1986
ELEVATION OF SERUM CA 125 PRIOR TO DIAGNOSIS OF AN EPITHELIAL OVARIAN-CARCINOMA
. 22:115-120.
1985
Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: A study of morbidity and survival
2004
The gastrointestinal complications of the Miami Pouch: A review of 77 cases
2004
Surgery "ain't" going to cut it. Are we ready?
2002
Re: Meta-analysis comparing cisplatin total dose intensity and survival: A critical reappraisal
1996
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan
1998
Untitled - Reply
1996
CECAL CANCER IN A TEENAGER PRESENTING WITH A PELVIC MASS - A CASE-REPORT AND REVIEW OF THE LITERATURE
1994
ANALYSIS FOR STEROID-PRODUCTION OF A SERTOLI-LEYDIG CELL TUMOR
1994
Why have ovarian cancer mortality rates declined? Part I. Incidence
2015
Why have ovarian cancer mortality rates declined? Part II. Case-fatality
2015
Why have ovarian cancer mortality rates declined? Part III. Prospects for the future
2015
Endometrial cancer: A review and current management strategies: Part I
2014
Endometrial cancer: A review and current management strategies: Part II
2014
The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer
2010
Who should operate on patients with ovarian cancer? An evidence-based review
2005
Systematic review of management options for women with a hereditary predisposition to ovarian cancer
2004
ADJUVANT THERAPY FOR NEUROENDOCRINE SMALL-CELL CARCINOMA OF THE CERVIX - REVIEW OF THE LITERATURE
1991
Fanconi anemia repair pathway as a predictor of anti-tumor activity of pembrolizumab: interim analysis of open-label, single-arm phase II trial
2021
Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].
2017
Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].
2017
Granulosa cell tumors: A SEER data review of prognostic parameters in 1815 patients
2017
Neoadjuvant chemotherapy and cycle number: A national multicentre study
2017
The sooner the better: Genetic testing following ovarian cancer diagnosis (vol 137, pg 423, 2015)
2017
Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy
2015
Endometrial cancer: A review and current management strategies: Part I (vol 134, pg 385, 2014)
2014
Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?
2014
Multi-center gene expression analysis of Mullerian low-grade and high-grade serous carcinoma highlights genes potentially involved in chemotherapy resistance
2012
Implementation of surgical treatment for early-stage cervical cancer by Kenyan gynecologists in western Kenya
2011
Saul B. Gusberg, MD. In memoriam
2005
TO P-32 OR NOT TO P-32, THAT IS THE QUESTION
1993
ASCITIC FLUID FROM OVARIAN-CANCER PATIENTS CONTAINS A UNIQUE GROWTH-FACTOR WHICH STIMULATES OVARIAN-CANCER CELLS - CHARACTERIZATION, PURIFICATION, AND MECHANISM OF ACTION
1988
Research
category
OBSTETRICS & GYNECOLOGY
Category
ONCOLOGY
Category
Identifiers
International Standard Serial Number (ISSN)
0090-8258
Electronic International Standard Serial Number (EISSN)
1095-6859
Other
journal abbreviation
GYNECOL ONCOL
